AZRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 rugs. 2021 @ 07:00):

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders...

Stats
Šios dienos apimtis	629 030
Vidutinė apimtis	713 030
Rinkos kapitalizacija	3.43M
EPS	$-1.600 ( 2021-08-16 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.845
ATR14	$0.0530 (1.54%)

Insider Trading

Date	Person	Action	Amount	type
2021-09-09	Coelho Mary Theresa	Buy	10 310	Stock option (right to buy)
2021-08-11	Coelho Mary Theresa	Buy	0
2021-07-09	Pennington James	Buy	100 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	250 000	Stock option (right to buy)
2021-06-30	Schneiderman Daniel H	Buy	35 006	Stock option (right to buy)

INSIDER POWER
0.00
Last 81 transactions
Buy: 5 836 949 \| Sell: 2 173 162

Tūris Koreliacija

Ilgas: -0.02 (neutral)

Trumpas: 0.65 (weak)

Signal:(72.656) Neutral

AzurRx BioPharma Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
GAINL	0.969
HILS	0.956
ALR	0.948
MBIN	0.948
PSTX	0.929
WINT	0.928
RELI	0.925
TYRA	0.924
LFMDP	0.922
SATL	0.921

10 Labiausiai neigiamai susiję koreliacijos
BOCH	-0.962
SHSP	-0.934
TBIO	-0.928
CCSI	-0.927
EYE	-0.925
MMAC	-0.921
ACHC	-0.909
PPYAU	-0.908
SY	-0.902
RCM	-0.897

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

AzurRx BioPharma Inc Koreliacija - Valiuta/Žaliavos

0.42
( neutral )

0.61
( weak )

0.00
( neutral )

0.40
( neutral )

0.21
( neutral )

-0.32
( neutral )

AzurRx BioPharma Inc Finansinės ataskaitos

Annual	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5 902 903

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5 902 903

FY	2019
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-6.77

FY	2018
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-8.77

Financial Reports:

No articles found.

AzurRx BioPharma Inc

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).